Stephen W. Fenwick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen W. Fenwick has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
G.J. Poston
3 shared publicationsH.Z. Malik
3 shared publicationsE. O'Grady
2 shared publicationsM. Terlizzo
2 shared publicationsA A Al-Sarira
North Western Hepatobiliary Unit, University Hospital Aintree, Liverpool L7 9AL, UK
1 shared publicationA. Smethurst
1 shared publication
Latest Publications
- Open Access
- 1 December 2018
- Published by Oxford University Press (OUP) in BJR|case reports
- Vol. 4 (4) , 20180008
Intra-peritoneal mature benign cystic teratoma deposits: an unusual complication from previous surgical resection of an ovarian mature benign cystic teratoma
In this case we describe multiple unusual intra-peritoneal lesions containing fat, soft tissue and calcification. These were found radiologically and histologically to be in keeping with mature benign cystic teratoma intraperitoneal deposits, also described as dermoid cysts. These were presumed to be due to seeding from surgical resection of ovarian mature benign cystic teratoma five years previously. This surgical complication has not been well documented thus far in the literature.
- 1 December 2018
- Published by Oxford University Press (OUP) in BJR|case reports
- Vol. 4 (4) , 20180008
Open AccessIntra-peritoneal mature benign cystic teratoma deposits: an unusual complication from previous surgical resection of an ovarian mature benign cystic teratoma
In this case we describe multiple unusual intra-peritoneal lesions containing fat, soft tissue and calcification. These were found radiologically and histologically to be in keeping with mature benign cystic teratoma intraperitoneal deposits, also described as dermoid cysts. These were presumed to be due to seeding from surgical resection of ovarian mature benign cystic teratoma five years previously. This surgical complication has not been well documented thus far in the literature.
- 1 February 2018
- Published by Elsevier in Cancer Epidemiology
- Vol. 52, 158-159
Re: E Morris, T Treasure, Cancer Epidemiology, 49 (2017) 152–155
- 1 February 2018
- Published by Elsevier in Cancer Epidemiology
- Vol. 52, 158-159
Re: E Morris, T Treasure, Cancer Epidemiology, 49 (2017) 152–155
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S125
315. MicroRNA-122 as a serum biomarker for hepatocellular carcinoma
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S125
315. MicroRNA-122 as a serum biomarker for hepatocellular carcinoma
- 19 December 2013
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (6) , 542-547
The Liverpool uveal melanoma liver metastases pathway: Outcome following liver resection
Aim: To determine the outcome of patients that underwent liver resection for metastases from uveal melanoma.Methods: Over a 9‐year period, patients referred with uveal melanoma metastases were included. Following treatment of primary uveal melanoma, high‐risk patients were offered to be enrolled into a 6‐monthly non‐contrast liver magnetic resonance imaging (MRI) surveillance. Following detection of liver metastases, patients were staged with a contrast‐enhanced (Primovist®) liver MRI, computer tomography (CT) of the thorax and staging laparoscopy.Results: 155 patients were referred with uveal melanoma liver metastases, of which 17 (11.0%) patients had liver resection and one patient was treated with percutaneous radio‐frequency ablation. The majority of patients undergoing liver resection were treated with multiple metastectomies (n = 8) and three patients had major liver resections. The overall median survival for patients treated with surgery/ablation was 27 (14–90) months, and this was significantly better compared to patients treated palliatively [median = 8(1–30) months, P < 0.001]. Following surgery, 11 patients had recurrent disease [median = 13(6–36) months]. Patients who had undergone a major liver resection had a significantly poorer disease‐free survival (P = 0.037).Conclusions: Patients who can undergo surgical resection for metastatic uveal melanoma have a more favorable survival compared to those who do not. J. Surg. Oncol. 2014 109:542–547.
- 19 December 2013
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (6) , 542-547
The Liverpool uveal melanoma liver metastases pathway: Outcome following liver resection
Aim: To determine the outcome of patients that underwent liver resection for metastases from uveal melanoma.Methods: Over a 9‐year period, patients referred with uveal melanoma metastases were included. Following treatment of primary uveal melanoma, high‐risk patients were offered to be enrolled into a 6‐monthly non‐contrast liver magnetic resonance imaging (MRI) surveillance. Following detection of liver metastases, patients were staged with a contrast‐enhanced (Primovist®) liver MRI, computer tomography (CT) of the thorax and staging laparoscopy.Results: 155 patients were referred with uveal melanoma liver metastases, of which 17 (11.0%) patients had liver resection and one patient was treated with percutaneous radio‐frequency ablation. The majority of patients undergoing liver resection were treated with multiple metastectomies (n = 8) and three patients had major liver resections. The overall median survival for patients treated with surgery/ablation was 27 (14–90) months, and this was significantly better compared to patients treated palliatively [median = 8(1–30) months, P < 0.001]. Following surgery, 11 patients had recurrent disease [median = 13(6–36) months]. Patients who had undergone a major liver resection had a significantly poorer disease‐free survival (P = 0.037).Conclusions: Patients who can undergo surgical resection for metastatic uveal melanoma have a more favorable survival compared to those who do not. J. Surg. Oncol. 2014 109:542–547.
- 1 April 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45, S255
OP-20 Radiological response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI®) for resectable liver metastases from colorectal cancer does not correlate with pathological response or long-term outcome
- 1 April 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45, S255
OP-20 Radiological response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI®) for resectable liver metastases from colorectal cancer does not correlate with pathological response or long-term outcome
- Open Access
- 14 June 2012
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 99 (8) , 1129-1136
Cholecystectomy-related bile duct and vasculobiliary injuries
Combined vasculobiliary injury is a serious complication of cholecystectomy. This study examined medium- to long-term outcomes after such injury. Patients referred to this institution with Strasberg type E bile duct injuries were identified from a prospectively maintained database (1990–2010). Long-term outcomes were evaluated by chart review. Sixty-three patients were referred with bile duct injury alone (45 patients) or vasculobiliary injury (18). Thirty patients (48 per cent) had septic complications before transfer. Twenty-six patients (41 per cent) had long-term biliary complications over a median follow-up of 96 (range 12–245) months. Nine patients (3 with bile duct injury, 6 with vasculobiliary injury) required further interventions after a median of 22 (8–38) months; five required biliary surgical revision and four percutaneous dilatation of biliary strictures. Vasculobiliary injury and injury-related sepsis were independent risk factors for treatment failure: hazard ratio 7·79 (95 per cent confidence interval 2·80 to 21·70; P < 0·001) and 4·82 (1·69 to 13·68; P = 0·003) respectively. Outcome following bile duct injury repair was worse in patients with concomitant vasculobiliary injury and/or sepsis.
- 14 June 2012
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 99 (8) , 1129-1136
Open AccessCholecystectomy-related bile duct and vasculobiliary injuries
Combined vasculobiliary injury is a serious complication of cholecystectomy. This study examined medium- to long-term outcomes after such injury. Patients referred to this institution with Strasberg type E bile duct injuries were identified from a prospectively maintained database (1990–2010). Long-term outcomes were evaluated by chart review. Sixty-three patients were referred with bile duct injury alone (45 patients) or vasculobiliary injury (18). Thirty patients (48 per cent) had septic complications before transfer. Twenty-six patients (41 per cent) had long-term biliary complications over a median follow-up of 96 (range 12–245) months. Nine patients (3 with bile duct injury, 6 with vasculobiliary injury) required further interventions after a median of 22 (8–38) months; five required biliary surgical revision and four percutaneous dilatation of biliary strictures. Vasculobiliary injury and injury-related sepsis were independent risk factors for treatment failure: hazard ratio 7·79 (95 per cent confidence interval 2·80 to 21·70; P < 0·001) and 4·82 (1·69 to 13·68; P = 0·003) respectively. Outcome following bile duct injury repair was worse in patients with concomitant vasculobiliary injury and/or sepsis.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 3560
Feasibility of neoadjuvant transarterial chemoembolization (TACE) using irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable colorectal liver metastases (RCLM): A phase II study.
3560 Background: Peri-operative chemotherapy confers 3-year disease free survival (DFS) advantage for patients with RCLM. However, studies to date have only examined multiple cycles of systemic neoadjuvant chemotherapy (SNC). Recent reports also correlate degree of postchemotherapy tumor necrosis (PCTN) to improved post-HPX DFS. The aim of this study is to examine the feasibility and safety of single DEBIRI TACE 1 month before HPX. Methods: Patients with unilobar (bilobar excluded) RCLM referred to 4 major centers offering HPX were evaluated for tumor number and localization, intention to recruit 20 patients. DEBIRI TACE is administered 1 month before HPX. Primary end-point is complication free TACE and HPX. Secondary end points include extent of PCTN and viable residual tumor (VRT), health economics, quality of life and subsequent DFS. PCTN and VRT centrally assessed by one blinded pathologist. Results: 22 patients screened; DEBIRI TACE attempted in 18; successful in 17; 13 have undergone HPX. DEBIRI TACE not possible in 5: 2 bilobar disease; 2 inconclusive angiography; 1 suspected hepatoma. No treatment related deaths (post- TACE or -HPX), 1 post-TACE liver abscess (recognised TACE complication), no significant post-HPX morbidity. VRT: 0% in 3 specimens; 5% in 1; 10% in 3; 30% in 2; 50% in 1; 60% in 1; 70% in 1; 75% in 1, all with commensurate PCTN. Conclusions: Neoadjuvant DEBIRI TACE is safe pre- HPX for RCLM and is not associated with any increased post-HPX complications. DEBIRI TACE resulted in ≥ 90% PCTN in 7/13 (50%) patients which may translate into significantly improved post-HPX DFS. Results of all 20 patients will be presented; recruitment is now extending to 50 patients. DEBIRI TACE may offer a cost-effective alternative to SNC in these patients.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 3560
Feasibility of neoadjuvant transarterial chemoembolization (TACE) using irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable colorectal liver metastases (RCLM): A phase II study.
3560 Background: Peri-operative chemotherapy confers 3-year disease free survival (DFS) advantage for patients with RCLM. However, studies to date have only examined multiple cycles of systemic neoadjuvant chemotherapy (SNC). Recent reports also correlate degree of postchemotherapy tumor necrosis (PCTN) to improved post-HPX DFS. The aim of this study is to examine the feasibility and safety of single DEBIRI TACE 1 month before HPX. Methods: Patients with unilobar (bilobar excluded) RCLM referred to 4 major centers offering HPX were evaluated for tumor number and localization, intention to recruit 20 patients. DEBIRI TACE is administered 1 month before HPX. Primary end-point is complication free TACE and HPX. Secondary end points include extent of PCTN and viable residual tumor (VRT), health economics, quality of life and subsequent DFS. PCTN and VRT centrally assessed by one blinded pathologist. Results: 22 patients screened; DEBIRI TACE attempted in 18; successful in 17; 13 have undergone HPX. DEBIRI TACE not possible in 5: 2 bilobar disease; 2 inconclusive angiography; 1 suspected hepatoma. No treatment related deaths (post- TACE or -HPX), 1 post-TACE liver abscess (recognised TACE complication), no significant post-HPX morbidity. VRT: 0% in 3 specimens; 5% in 1; 10% in 3; 30% in 2; 50% in 1; 60% in 1; 70% in 1; 75% in 1, all with commensurate PCTN. Conclusions: Neoadjuvant DEBIRI TACE is safe pre- HPX for RCLM and is not associated with any increased post-HPX complications. DEBIRI TACE resulted in ≥ 90% PCTN in 7/13 (50%) patients which may translate into significantly improved post-HPX DFS. Results of all 20 patients will be presented; recruitment is now extending to 50 patients. DEBIRI TACE may offer a cost-effective alternative to SNC in these patients.